All Search Results
News Releases
Sep 14, 2026, 10:31 ET Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
practices, addressable patient population, which includes top indications such as Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis,
More news about: DelveInsight Business Research, LLP
Aug 14, 2026, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
pre-treated gynecologic malignancies. Additionally, Phase 1 data of LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory DLBCL, presented at the 2026 ASTCT® & CIBMTR® Tandem Meetings, showed an 86% objective response rate, including 57% complete response,
More news about: Citius Pharmaceuticals, Inc.
Aug 14, 2026, 16:30 ET Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
and,Phase 1 data for LYMPHIR administered prior to CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL) presented at 2026 ASTCT® & CIBMTR® Tandem Meetings, demonstrating:86% ORR, including 57% complete response
More news about: Citius Oncology, Inc.
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
glofitamab. As the Company continues to commercialize ZYNLONTA in the 3L+ DLBCL setting, we will work closely with the FDA to determine how to best obtain full approval and to advance ZYNLONTA combinations into earlier lines of therapy in DLBCL."We are pleased by our second quarter performance, which reflects
More news about: ADC Therapeutics SA
Aug 02, 2026, 10:01 ET New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for ASCT. Monjuvi is not indicated and is not recommended for
More news about: Specialised Therapeutics
